Biological therapy for systemic vasculitis: A systematic review

摘要: Abstract Objective Relapses and failure are frequent in systemic vasculitis (SV) patients. Biological agents have been prescribed as rescue therapies. The aim of this systematic review is to analyze the current evidence on therapeutic use biological for SV. Methods MEDLINE, EMBASE, Cochrane Database Systematic Reviews, Central Register Controlled Trials were searched up end April 2013. reviews meta-analysis, clinical trials, cohort studies, case series with >3 patients included. Independent article study quality assessment was done by 2 investigators consensus resolution discrepancies. Results Of 3447 citations, abstracts, hand-searched studies screened, 90 Most included ANCA-associated (AAV) only a few large vessel (LVV) Rituximab most used agent, having demonstrated efficacy remission induction AAV. A number different anti-TNFα contrasting results. uncontrolled abatacept, alemtuzumab, mepolizumab, tocilizumab found. Conclusion Current therapies SV mainly based uncontrolled, observational data. not inferior cyclophosphamide AAV might be superior relapsing disease. Infliximab adalimumab effective steroid-sparing agents. Etanercept maintain granulomatosis polyangiitis, serious adverse events reported. For LVV, both infliximab etanercept had role agents, also LVV.